ziltivekimab

ESC 2022 – Novo’s cardiovascular charge continues
EP Vantage
Thu, 09/1/22 - 10:13 am
ESC 2022
Novo Nordisk
ziltivekimab
PRX004
HS-001
Novo Nordisk continues pushing beyond diabetes, netting PhII win for former Corvidia kidney program
Endpoints
Tue, 05/18/21 - 11:00 am
Novo Nordisk
chronic kidney disease
clinical trials
ziltivekimab